| Document |
Document Title |
|
JP2015120693A |
To provide new processes for preparing and purifying lubiprostone.A process involves 1,4-conjugate addition of a higher order cuprate compound to a protected cyclopentenone intermediate as an important preparation step. Obtained lubipros...
|
|
JP5734302B2 |
The crystalline form A of Bimatoprost of formula I, its preparation method and use are provided. There are characteristic peaks where diffraction angles 2¸ are 3.2±0.2°, 5.5±0.2°, 11.4±0.2°, 16.7±0.2°, 17.6±0.2°, 19.9±0.2°, ...
|
|
JP5653827B2 |
A process for the preparation of prostaglandin compounds having the formula (I); wherein A is selected from the group consisting Of C1-C6 alkyl; C7-C16 aralkyl wherein the aryl group is optionally substituted with one to three substituen...
|
|
JP2014221776A |
To provide compounds useful for reducing intraocular pressure.There are provided cyclopentane compounds having prostaglandin activity represented by the formula in the figure, and their use in producing therapeutic drugs for ocular hyper...
|
|
JP5579158B2 |
A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.
|
|
JP5570807B2 |
A compound having a formula is disclosed herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
|
|
JP5568021B2 |
Disclosed is a novel use of a prostaglandin compound as a chloride channel opener. According to the instant invention, chloride channels in a mammalian subject can be opened by a prostaglandin compound to facilitate chloride ion transpor...
|
|
JP5566912B2 |
11,15,19-trihydroxy-9-halo-prostaglandin analogues to be used as hair growing agent.
|
|
JP5554888B2 |
A method for preparing cyclopentanones or lactones is provided to be useful for preparation of prostagladins, to remove problems such as the long synthesis route and the removal of undesired isomers, and thus achieves a simple and econom...
|
|
JP5528351B2 |
|
|
JP5532302B2 |
Disclosed herein are compounds of the formula therapeutic methods, compositions, and medicaments related thereto are also disclosed.
|
|
JP5490155B2 |
The present invention relates to a process for preparing a prostaglandin derivative and an intermediate therefor. In accordance with the present invention, the prostaglandin F (PGF) derivative can be efficiently prepared with high purity...
|
|
JP5485980B2 |
A process for preparing a prostaglandin analogue comprising a step of converting a compound of formula (8′): to the prostaglandin analogue, wherein R3 represents hydrogen or a hydroxyl protecting group.
|
|
JP5410271B2 |
Compounds having a structure are disclosed herein (Formula I). Compositions, methods, and medicaments related to the therapeutic use of these compounds are also disclosed.
|
|
JP5401540B2 |
Nitroderivatives of prostaglandins having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
|
|
JP5387699B2 |
A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP 4 agonist as an active ingredient. An EP 4 agonist, in which includes a compound p...
|
|
JP5377970B2 |
The present invention relates to a method for treating chronic obstructive pulmonary disease in a mammalian subject, which comprises administering an effective amount of a specific bicyclic compound of formula (I): and/or a tautomer ther...
|
|
JP5330324B2 |
The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to the following formula: wherein R1, R2, R3, R4, X, and Z are as defined. This invention also includes opti...
|
|
JP5318288B2 |
A process for the synthesis and purification of F-series prostaglandin compounds and synthetic intermediates used to prepare them. The synthetic intermediates are solid and may be purified by precipitation and therefore may form the repr...
|
|
JP5319065B2 |
The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the gener...
|
|
JP5318837B2 |
The present invention provides prostaglandin compounds having two hetero atoms at the 15 position which are useful for promoting hair growth in a mammal.
|
|
JP2013534222A |
A composition comprising a compound of the formula (I) wherein the dashed bonds represent a single or double bond; R and R' are individually selected from the group consisting of hydrogen, a C1-C6 straight or branched chain alkyl that ma...
|
|
JP5247680B2 |
A compound having a structure is disclosed herein. Compositions, medicaments, and therapeutic methods related thereto are also disclosed.
|
|
JP5222462B2 |
Provided is an ophthalmic composition comprising a prostaglandin compound and viscosity-increasing compound. This composition, by virtue of the addition of the viscosity increasing compound, realizes stabler exertion of the activity and ...
|
|
JP2013082741A |
To provide a novel method of producing prostamide.The method of producing prostamide includes the steps of: (a) generating a second intermediate represented by Formula (II) by a reaction between a first intermediate represented by Formul...
|
|
JP5147404B2 |
The present invention provides a method and composition for treating a central nervous system disorder in a mammalian subject, which comprises administering an effective amount of a 11-deoxy-prostaglandin compound to a subject in need th...
|
|
JP5114205B2 |
Disclosed herein are compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof; wherein Y, A, B, J, and E are further described. Methods, compositions, and medicaments related thereto are also disclosed.
|
|
JP5073588B2 |
Disclosed is a method for promoting bile secretion, which comprises administering and effective amount of a certain 15-keto-prostaglandin compound to a subject having a disease or condition associated with bile secretion deficient. Also ...
|
|
JP5052423B2 |
Disclosed is a method for treatment of external secretion disorders, which comprises administering a fatty 5 acid derivative to a subject in need of said treatment. The method of the present invention is useful for treatment of at least ...
|
|
JP5023492B2 |
It is intended to provide highly safe and efficacious blood flow promoters for cauda equina tissues. Among prostaglandin-like compounds having a weak hypotensive effect, compounds having an effect of promoting the blood flow in cauda equ...
|
|
JP2012519163A |
The invention concerns a new process for the preparation of prostaglandin derivatives, in particular prostaglandin F2α derivatives, for example bimatoprost, latanoprost and travoprost, the new intermediates of said process and their use...
|
|
JP4985400B2 |
A prostaglandin derivative represented by the formula: (I) wherein R1 represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or an alkenyl group having 2 to 4 carbon atoms; X represents an ethylene group, a trimethylene gr...
|
|
JP4973650B2 |
A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP 4 agonist as an active ingredient. An EP 4 agonist, in which includes a compound p...
|
|
JP2012511027A |
The invention provides compositions or pharmaceutical compositions of novel high penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capabl...
|
|
JP2012507552A |
The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.
|
|
JP4851467B2 |
Disclosed is a method for preparing a prostaglandin derivative of formula (A): which comprises reacting an aldehyde represented by formula (1): with a 2-oxoalkyl phosphonate in a reaction solvent under the presence of alkali hydroxide as...
|
|
JP4834224B2 |
Compounds having the general structure: which are useful for the treatment of a variety of diseases and conditions, such as bone disorders.
|
|
JP4786866B2 |
Disclosed is a novel use of a prostaglandin compound as a chloride channel opener. According to the instant invention, chloride channels in a mammalian subject can be opened by a prostaglandin compound to facilitate chloride ion transpor...
|
|
JP4764828B2 |
A process for the preparation of prostaglandin compounds having the formula (I); wherein A is selected from the group consisting Of C1-C6 alkyl; C7-C16 aralkyl wherein the aryl group is optionally substituted with one to three substituen...
|
|
JP2011132257A |
To provide a highly safe and efficacious blood flow promotor for cauda equina tissues.The blood flow promotor for cauda equina tissues comprises a compound expressed by formula (I-1) (wherein a ring A1 is a 5-6 membered monocyclic nitrog...
|
|
JP4690814B2 |
The present invention provides a new method for manufacturing a prostaglandin analogue having one or more keto groups on the 5-membered ring and/or omega chain, which comprises the step of treating a corresponding hydroxyl group containi...
|
|
JP2011515406A |
Therapeutic compounds are disclosed herein. Methods, compositions, and medicaments related thereto are also disclosed. The compounds described herein are used to treat ocular conditions, bowel disease and baldness.
|
|
JP2011515406T |
The compound for medical treatment is indicated in this specification. The method, the constituent, and medical supplies in relation to those compounds are also indicated. The compound indicated on these specifications is used for treati...
|
|
JP2011515409T |
The compound containing the following, the salt which can be permitted on the medicine manufacture, or its prodrug is indicated: [Formula 1]((I) -- the inside of a formula, Y, A, and R1R2Z and G are as explaining. The method, the constit...
|
|
JP2011515409A |
Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, R1, R2, Z, and G are as described. Methods, compositions, and medicaments related thereto are also disclosed.
|
|
JP2011052014A |
To provide an effective ocular hypotensive agent and a widely applicable smooth muscle relaxant.A cyclopentaneheptanoic acid, 2-cycloalkyl or arylalkyl derivative substituted with halo, methyl, hydroxy, nitro, amino, amide, azide, oxime,...
|
|
JP4648340B2 |
Disclosed is an improved method for preparing 15-keto-prostaglandin E derivative. According to the invention, the deprotection of protected hydroxy group required in manufacturing a 15-keto-prostaglandin derivative is conducted under the...
|
|
JP4642021B2 |
The present invention provides prostaglandin compounds having two hetero atoms at the 15 position which are useful for promoting hair growth in a mammal.
|
|
JP2011037861A |
To provide a new PGF (prostaglandin F) analogue useful in treating various diseases and symptoms including bone disorders.A compound having a structure in accordance with formula (I) is provided. Besides, optical isomers, diastereomers a...
|
|
JP4619531B2 |
The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to the following formula: wherein R1, R2, R3, R4, X, and Z are as defined. This invention also includes opti...
|
